Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends

被引:35
|
作者
Piatkiewicz T.J. [1 ]
Traulsen J.M. [1 ]
Holm-Larsen T. [2 ,3 ]
机构
[1] Section for Social and Clinical Pharmacy, Department of Pharmacy, University of Copenhagen, Universitetsparken 2, Copenhagen
[2] Pharma Evidence, Farum
[3] Nopia Research Group, Department of Urology, Ghent University Hospital, Ghent
关键词
D O I
10.1007/s41669-017-0044-1
中图分类号
学科分类号
摘要
Objective: Our objectives were to explore the changes in the level of interest in risk-sharing agreements (RSAs) in the EU during the last 15 years and the underlying reasons for these changes. Methods: A systematic literature review was conducted using PubMed, Scopus, Web of Science, and Embase. Articles identified were divided into ‘quantitative articles’ used to establish the level of interest and ‘qualitative articles’ used to identify the underlying trends in RSAs. Results: The literature search retrieved 2144 scientific articles. Data were extracted from 238 articles. Of these, 100 contained quantitative data and 138 contained qualitative data. The pace of articles being published about RSAs grew significantly in 2015, which related to the increase in interest in and knowledge about RSAs. The underlying reasons for the fluctuations were condensed into four overall themes: (1) push for value-based pricing, (2) economic crisis and further push to contain costs, (3) criticism of RSAs in the real world, and (4) diversification of RSAs to fit the purpose. Conclusion: The overall level of interest in RSAs in the EU has been increasing since 2000; therefore, articles reporting the number of RSAs implemented and case studies have been steadily growing as evidence is becoming more readily available. The number of qualitative articles reporting and discussing the underlying reasons for these changes in interest has largely fluctuated over the last 15 years. Despite these fluctuations, interest in RSAs remains high. © 2017, The Author(s).
引用
收藏
页码:109 / 123
页数:14
相关论文
共 50 条
  • [1] MAJOR TRENDS AND IMPLEMENTATION OF RISK-SHARING AGREEMENTS IN CHINA: A SYSTEMATIC REVIEW
    Lou, S.
    Xing, Y.
    Wu, Y.
    Wu, M.
    Wang, R.
    Jiang, B.
    Xiong, T.
    VALUE IN HEALTH, 2020, 23 : S299 - S299
  • [2] Pharmaceutical Risk-Sharing Agreements
    Afschin Gandjour
    PharmacoEconomics, 2009, 27 : 431 - 432
  • [3] Pharmaceutical Risk-Sharing Agreements
    Joseph P. Cook
    John A. Vernon
    Richard Manning
    PharmacoEconomics, 2008, 26 : 551 - 556
  • [4] Pharmaceutical risk-sharing agreements
    Cook, Joseph P.
    Vernon, John A.
    Manning, Richard
    PHARMACOECONOMICS, 2008, 26 (07) : 551 - 556
  • [5] Pharmaceutical Risk-Sharing Agreements
    Gandjour, Afschin
    PHARMACOECONOMICS, 2009, 27 (05) : 431 - 432
  • [6] POTENTIAL RISK-SHARING AGREEMENTS FOR VACCINES
    Terlinden, A.
    Ethgen, O.
    Demarteau, N.
    Curran, D.
    VALUE IN HEALTH, 2014, 17 (07) : A669 - A670
  • [7] Where Are We on "Risk-Sharing" Agreements?
    Neumann, Peter J.
    VALUE IN HEALTH, 2013, 16 (05) : 701 - 702
  • [8] Risk-sharing agreements, present and future
    Goncalves, Francisco R.
    Santos, Susana
    Silva, Catarina
    Sousa, Gabriela
    ECANCERMEDICALSCIENCE, 2018, 12
  • [9] Private Sector Risk-Sharing Agreements in the United States: Trends, Barriers, and Prospects
    Garrison, Louis P., Jr.
    Carlson, Josh J.
    Bajaj, Preeti S.
    Towse, Adrian
    Neumann, Peter J.
    Sullivan, Sean D.
    Westrich, Kimberly
    Dubois, Robert W.
    AMERICAN JOURNAL OF MANAGED CARE, 2015, 21 (09): : 632 - +
  • [10] Italian risk-sharing agreements on drugs: are they worthwhile?
    Livio Garattini
    Alessandro Curto
    Katelijne van de Vooren
    The European Journal of Health Economics, 2015, 16 : 1 - 3